Tag: Oral

Natural Ways to Whiten Your Teeth at Home

February 19, 2023
baking sodaBrighthydrogen peroxideLifestyleOralteethteeth carewhitening
0 Comment

A bright smile may be the first thing you notice about a person, but a closer look could reveal that their teeth are less than bright. The majority of Americans desire whiter teeth, and millions are spent each year on over-the-counter and in-office treatments to achieve this goal. As a result, many have wondered if…

Read More

Japan’s Shionogi Seeks Approval for COVID-19 Pill

February 26, 2022
Asia & PacificCCP VirusCOVID-19drugmakerJapanOralpillShionogiWorld
0 Comment

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said…

Read More

Pfizer Says It Applied for Japan Government’s Approval for Oral COVID-19 Drug

January 14, 2022
Asia & PacificBrightBusiness & EconomyCCP VirusCompaniesCOVID-19drugHealth NewsJapanMind & BodyOralPfizerWorld
0 Comment

TOKYO—U.S. drugmaker Pfizer Inc. said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment. The application is based on global Phase II/III trials that Japan was part of, Pfizer said in a statement. With COVID-19 cases surging again, Japan is betting heavily on oral treatments to keep serious infections and…

Read More

How Much Revenue Could Pfizer’s Oral COVID-19 Pill Fetch?

December 25, 2021
Business & EconomyCCP VirusCompanieseconomyOralPfizerpillrevenueUncategorizedVaccines & Safety
0 Comment

Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. Pfizer Analysts SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased…

Read More